Nurix Therapeutics (NRIX) Total Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has 3 years of Total Non-Current Liabilities data on file, last reported at $117.1 million in Q3 2021.

• On a quarterly basis, Total Non-Current Liabilities rose 13.23% year-over-year to $117.1 million in Q3 2021; TTM through Aug 2021 was $117.1 million, a 13.23% increase from a year earlier, with the FY2020 full-year figure at $105.2 million, up 103.02% from the prior year.
• Total Non-Current Liabilities for Q3 2021 stood at $117.1 million, down from $119.0 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for NRIX reached as high as $125.7 million in Q1 2021 and fell as low as $51.8 million in Q4 2019.
• Historically, Total Non-Current Liabilities has averaged $103.7 million across 3 years, with a median of $111.1 million in 2020.
• Across the five-year window, Total Non-Current Liabilities surged 103.02% in 2020 and climbed 13.23% in 2021, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $51.8 million in 2019, then jumped by 103.02% to $105.2 million in 2020, then grew by 11.25% to $117.1 million in 2021.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $117.1 million in Q3 2021, $119.0 million in Q2 2021, and $125.7 million in Q1 2021.